Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

Chung, HC; Bang, YJ; Tabernero, J; Van Cutsem, E; Fuchs, CS; Wyrwicz, L; Lee, KW; Kudaba, I; Garrido, M; Castro, H; Mansoor, W; Braghiroli, MI; Goekkurt, E; Chao, J; Wainberg, ZA; Kher, U; Shah, S; Shitara, K

ANNALS OF ONCOLOGY, 2019; 30 ():